Search

Search Constraints

You searched for: Author/Creator Ponikowski, P

Search Results

1. 5222Muscle-derived follistatin and decorin levels in men with heart failure with reduced ejection fraction and different iron status. (28th August 2018)

4. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. (25th November 2020)

5. Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial. (14th October 2021)

6. Efficacy of intravenous ferric carboxymaltose for iron deficiency following acute heart failure (AHF) in patients with previously diagnosed HF: a subgroup analysis of AFFIRM-AHF. (26th April 2021)

7. Efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency with and without anaemia: a subgroup analysis of AFFIRM-AHF. (14th October 2021)

8. Elevated markers of liver function are associated with poorer outcomes in HFREF: an analysis of DAPA-HF. (14th October 2021)

9. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Issue 1 (January 2022)

10. Exaggerated blood pressure response at mild exertional intensity is associated with lower exercise capacity and worsening of cardiac structural and functional profile. (25th November 2020)